허혈성 심장질환 환자에서 스타틴과 병용하는 항혈소판제 종류에 따른 임상결과
Clinical Outcomes of Antiplatelets Combined with Statins in Patients with Ischemic Heart Disease
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Patients with cardiovascular risks are recommended to use statins and antiplatelet agents to prevent major cerebrocardiovascular events (MACCE). Antiplatelet agents also possess anti-inflammatory and antioxidant effects, in addition to their inhibitory activity on platelets. The differences in clinical outcomes in ischemic heart disease (IHD) based on the type of antiplatelet therapy combined with statin treatment were investigated in this study. Methods: We conducted a retrospective cohort study using electronic medical records of IHD patients from January 2010 to December 2014 at Ajou University Hospital. Patients on combination therapy of antiplatelet drugs and statins were grouped based on antiplatelet drug types: clopidogrel, cilostazol, or sarpogrelate. Propensity score matching was applied to balance the baseline of the groups of clopidogrel vs. cilostazol and the groups of clopidogrel vs. sarpogrelate. The incidence and risk of MACCE as primary outcomes were assessed between the groups of antiplatelet drugs. Results: Among the approximately 128,500 patients with IHD, 1,049 patients had taken a combination therapy of statin and antiplatelet agents. The cohorts of patients administered clopidogrel, cilostazol, or sarpogrelate were 906, 79, and 64, respectively. The incidence of MACCE was not significantly different among the cohorts (p=0.58), and there were no differences between clopidogrel vs. cilostazol (p=0.72) or clopidogrel vs. sarpogrelate (p=1.00) after propensity score matching. Conclusion: There was no difference in the incidence of MACCE based on the type of antiplatelet drug (clopidogrel, cilostazol, or sarpogrelate) in combination with a statin in patients with IHD.
Abstract
Background: Patients with cardiovascular risks are recommended to use statins and antiplatelet agents to prevent major cerebrocardiovascular events (MACCE). Antiplatelet agents also possess anti-inflammatory and antioxidant effects, in addition to their inhibitory activity on platelets. The differences in clinical outcomes in ischemic heart disease (IHD) based on the type of antiplatelet therapy combined with statin treatment were investigated in this study. Methods: We conducted a retrospective cohort study using electronic medical records of IHD patients from January 2010 to December 2014 at Ajou University Hospital. Patients on combination therapy of antiplatelet drugs and statins were grouped based on antiplatelet drug types: clopidogrel, cilostazol, or sarpogrelate. Propensity score matching was applied to balance the baseline of the groups of clopidogrel vs. cilostazol and the groups of clopidogrel vs. sarpogrelate. The incidence and risk of MACCE as primary outcomes were assessed between the groups of antiplatelet drugs. Results: Among the approximately 128,500 patients with IHD, 1,049 patients had taken a combination therapy of statin and antiplatelet agents. The cohorts of patients administered clopidogrel, cilostazol, or sarpogrelate were 906, 79, and 64, respectively. The incidence of MACCE was not significantly different among the cohorts (p=0.58), and there were no differences between clopidogrel vs. cilostazol (p=0.72) or clopidogrel vs. sarpogrelate (p=1.00) after propensity score matching. Conclusion: There was no difference in the incidence of MACCE based on the type of antiplatelet drug (clopidogrel, cilostazol, or sarpogrelate) in combination with a statin in patients with IHD.
참고문헌 (29)
- "Healthcare Bigdata hub"[URL]
- Grundy SM, "2018 American Heart Association", American College of Cardiology Multisociety Guideline on the management of blood cholesterol: primary prevention, 2019, pp.4(5), 488~489
- Grundy SM, "2018 American Heart Association", American College of Cardiology, JAMA Cardiol, pp.2019, 4(6)[DOI]
- Eikelboom JW, "Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines", Chest, 141, pp.e89S~e119S (2012)
- Levine GN, "2016 ACC", AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology, J Am Coll Cardiol, pp.2016, 68[DOI]
- Johansen ME, "Antiplatelet and statin use in US patients With coronary artery disease categorized by race", ethnicity and gender, 2003 to 2012, 2015, pp.115, 1507~1512
- 예경남, "관상동맥 약물 용출 스텐트 삽입 후 항혈소판제제 3제요법과 2제요법의 임상적 효과 비교", 한국임상약학회지, 22(2), pp.113~122 (2012), 한국임상약학회[DOI]
- Noh Y, "Antiplatelet therapy of cilostazol or sarpogrelate with aspirin and clopidogrel after percutaneous coronary intervention: a retrospective cohort study using the Korean national health insurance claim database", PLoS One, 11, pp.e0150475~ (2016)
- Nakao T, "The long-term efficacy of cilostazol in addition to dual antiplatelet therapy after sirolimuseluting stent implantation for Japanese patients: an analysis of the 3-year follow-up outcomes from the j-Cypher registry", Cardiovasc Interv Ther, 27, pp.161~167 (2012)
- Shim CY, "The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation", Int J Cardiol, 134, pp.351~355 (2009)
- Kim JY, "Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention", Circ J, 71, pp.1867~1872 (2007)
- Aoki C, "Antiinflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo", J Atheroscler Thromb, 17, pp.503~509 (2010)
- Aoki M, "Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model", Diabetologia, 44, pp.1034~1042 (2001)
- Ogawa S, "Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes", Clin J Am Soc Nephrol, 3, pp.362~368 (2008)
- Jeong IS, "Oral sarpogrelate can improve endothelial dysfunction as effectively as oral cilostazol, with fewer headaches, in active young male smokers", Heart Vessels, 28, pp.578~582 (2013)
- Hidaka S, "Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease", Ren Fail, 35, pp.43~48 (2013)
- Murphy B, "A general SAS® macro to implement optimal N: 1 propensity score matching within a maximum radius", 13~ (2017)
- "An introduction to implementing propensity score matching with SAS® 2010"[URL]
- Knuuti J, "2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)", Eur Heart J (2019)[DOI]
- Kim IS, "Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study", Br J Clin Pharmacol, 73, pp.629~640 (2012)
- Han Y, "Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study", Am Heart J, 157, pp.733~739 (2009)
- Hafez HM, "Nephroprotective effect of cilostazol and verapamil against thioacetamide-induced toxicity in rats may involve Nrf2", HO-1, Toxicol Mech Methods, pp.2019, 29[DOI]
- Noh Y, "Effects of cilostazol and reninangiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study", Int J Clin Pharm, 40, pp.160~168 (2018)
- 박정현, "Amelioration of high fat diet-induced nephropathy by cilostazol and rosuvastatin", Archives of Pharmacal Research, 40(3), pp.391~402 (2017), 대한약학회
- Tang WH, "Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial", Endocrine, 45, pp.293~301 (2014)
- Park, K-Y, "Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low-density lipoprotein receptor knockout mice", Cardiovasc Ther, 36, pp.e12476~ (2018)
- So Ree Kim, "Effect of sarpogrelate and high‐dose statin on the reduction of coronary spasm in vasospastic angina: A two by two factorial, pilot randomized study", Clinical Cardiology, 42(10), pp.899~907 (2019), Wiley[DOI]
- Yoo H, "Effects of sarpogrelate on microvascular complications with type 2 diabetes", Int J Clin Pharm, 41, pp.563~573 (2019)
- Nomura S, "Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliteransrelated biomarkers in patients with type 2 diabetes (SAREPITASO study)", Vasc Health Risk Manag, 14, pp.225~232 (2018)